ACTA1 and familial pancreatic carcinoma: Some of these stromal targets are being evaluated in pancreatic cancer, either by depleting CAFs using CAF-related cell-surface markers, such as α-SMA or FAP, reprogramming CAFs into quiescent fibroblasts, or targeting interactions between CAFs and their surrounding microenvironment [33].